Home > Publications Database > Anti-neuronal and anti-mitochondrial autoantibodies are associated with lower functional status and more severe respiratory symptoms in post COVID syndrome. > print

001     281503
005     20251102002042.0
024 7 _ |a 10.3389/fimmu.2025.1642250
|2 doi
024 7 _ |a pmid:40995367
|2 pmid
024 7 _ |a pmc:PMC12454094
|2 pmc
024 7 _ |a altmetric:181532850
|2 altmetric
037 _ _ |a DZNE-2025-01124
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Vogelgesang, Antje
|b 0
245 _ _ |a Anti-neuronal and anti-mitochondrial autoantibodies are associated with lower functional status and more severe respiratory symptoms in post COVID syndrome.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761731128_30627
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We previously identified IgG autoantibodies targeting epitopes within brainstem proteins-disabled homolog 1 (DAB1), apoptosis-inducing factor 1 (AIFM1), and surfeit locus protein 1 (SURF1)-as markers of severe acute COVID-19. This study investigates whether the same autoantibodies contribute to the pathophysiology of Post COVID Syndrome (PCS).Using a multiplexed bead-based immunoassay, we measured IgG levels against 18 synthetic peptides derived from DAB1, AIFM1, and SURF1 in serum samples from 45 PCS patients and 30 post-COVID controls without long-term symptoms. We employed generalized linear mixed models (GLMM) and nonlinear principal component analysis (CATPCA) to explore associations between antibody levels and clinical variables, including functional status (PCFS), respiratory symptoms, fatigue, cognitive impairment (as assessed by the Montreal Cognitive Assessment, MoCA), and mood.Higher IgG levels against the three autoantigens significantly predicted PCS at 3 months postinfection (t=2.21, p=0.03), whereas antibodies against a control peptide (polio) showed no such association. CATPCA identified a principal component capturing respiratory symptoms and functional impairment (PCFS), which was also significantly predicted by autoantibody levels (t=2.04, p=0.04). MoCA scores did not correlate with autoantibody levels, and subjective cognitive complaints were paradoxically linked to lower antibody titers and fewer physical symptoms.The findings from the present explorative study, although largely correlative, appear to suggest a sustained autoimmune response targeting neuronal and mitochondrial proteins in PCS, particularly associated with respiratory dysfunction and reduced functional capacity. The results also highlight potential limitations of standard cognitive screening tools like the MoCA in detecting subtle deficits in PCS. The identified autoantibodies may serve as biomarkers for persistent post-COVID disability. Future research replicating present results on larger samples and specifically investigating a causal link between occurrence of the Auto-Abs and PCS is needed for shaping future immunomodulatory therapeutic strategies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a autoantibodies
|2 Other
650 _ 7 |a autoimmunity
|2 Other
650 _ 7 |a brainstem
|2 Other
650 _ 7 |a mitochondria
|2 Other
650 _ 7 |a post COVID
|2 Other
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin G
|2 NLM Chemicals
650 _ 7 |a Mitochondrial Proteins
|2 NLM Chemicals
650 _ 7 |a Autoantigens
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Membrane Proteins
|2 NLM Chemicals
650 _ 7 |a Nerve Tissue Proteins
|2 NLM Chemicals
650 _ 7 |a Adaptor Proteins, Signal Transducing
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Autoantibodies: blood
|2 MeSH
650 _ 2 |a Autoantibodies: immunology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a COVID-19: immunology
|2 MeSH
650 _ 2 |a COVID-19: complications
|2 MeSH
650 _ 2 |a SARS-CoV-2: immunology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Immunoglobulin G: blood
|2 MeSH
650 _ 2 |a Immunoglobulin G: immunology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Mitochondria: immunology
|2 MeSH
650 _ 2 |a Mitochondrial Proteins: immunology
|2 MeSH
650 _ 2 |a Autoantigens: immunology
|2 MeSH
650 _ 2 |a Neurons: immunology
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Post-Acute COVID-19 Syndrome
|2 MeSH
650 _ 2 |a Membrane Proteins: immunology
|2 MeSH
650 _ 2 |a Nerve Tissue Proteins: immunology
|2 MeSH
650 _ 2 |a Adaptor Proteins, Signal Transducing: immunology
|2 MeSH
700 1 _ |a Steinmetz, Anke
|b 1
700 1 _ |a Stufano, Angela
|b 2
700 1 _ |a Schino, Valentina
|b 3
700 1 _ |a Plantone, Domenico
|b 4
700 1 _ |a Flöel, Agnes
|0 P:(DE-2719)2812683
|b 5
|u dzne
700 1 _ |a Lucchese, Guglielmo
|b 6
773 _ _ |a 10.3389/fimmu.2025.1642250
|g Vol. 16, p. 1642250
|0 PERI:(DE-600)2606827-8
|p 1642250
|t Frontiers in immunology
|v 16
|y 2025
|x 1664-3224
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281503/files/DZNE-2025-01124.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281503/files/DZNE-2025-01124.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281503
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2812683
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-12-29T15:23:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-12-29T15:23:07Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-12-29T15:23:07Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
920 1 _ |0 I:(DE-2719)5000081
|k AG Flöel
|l Dementia Prevention – Mechanisms and Clinical Implementation
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000081
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21